6M
6MK.F Merck & Co. Inc
- Market cap
- EUR 325B
- P/E
- 153.4x
- P/B
- 8.12x
- ROE
- -1.5%
- Dividend yield
- 2.29%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is 6MK.F undervalued?
Graham numberThe Graham number of Merck & Co. Inc cannot be estimated reliably (the estimate is too far from the market price).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Merck & Co. Inc fundamental analysis
No fundamental analysis for Merck & Co. Inc yet.
Merck & Co. Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Merck & Co. Inc
Merck & Co., Inc. operates as a healthcare company worldwide. It offers human health pharmaceutical for various areas under the Keytruda, Keytruda Qlex, Welireg, Gardasil, ProQuad, M-M-R II, Varivax, Vaxneuvance, Capvaxive, RotaTeq, Pneumovax 23, Bridion, Prevymis, Dificid, Zerbaxa, Winrevair, Adempas/ Verquvo, Ohtuvayre, Lagevrio, Isentress/Isentress HD, Delstrigo, Pifeltro, Belsomra, Januvia, and Janumet brands. The company also provides veterinary pharmaceuticals, vaccine…
Full company profileMerck & Co. Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Merck & Co. Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 39.8B | 40.1B | 42.3B | 46.8B | 48.0B | 48.7B | 59.3B | 60.1B | 64.2B | 65.0B | 68.0B |
| Gross Profit | 25.9B | 27.3B | 28.8B | 32.7B | 32.5B | 35.1B | 41.9B | 44.0B | 49.0B | 48.6B | 50.0B |
| Operating Income | 6.03B | 7.31B | 8.93B | 12.2B | 8.48B | 13.2B | 18.3B | 2.95B | 20.2B | 22.1B | 2.85B |
| EBITDA | - | 11.9B | 14.0B | 16.0B | 13.2B | - | 21.3B | 6.91B | 25.7B | 28.3B | 10.4B |
| Net Income | 3.92B | 2.39B | 6.22B | 9.84B | 7.07B | 13.0B | 14.5B | 365M | 17.1B | 18.3B | -680M |
| EPS | - | 0.89 | 2.40 | 3.88 | 2.79 | 5.16 | 5.72 | 0.14 | 6.77 | 7.38 | -0.28 |
| Balance Sheet | |||||||||||
| Total Assets | 95.4B | 87.9B | 82.6B | 84.4B | 91.6B | 106B | 109B | 107B | 117B | 137B | 133B |
| Total Liabilities | 55.1B | 53.3B | 55.8B | 58.4B | 66.2B | 67.4B | 63.1B | 69.0B | 70.7B | 84.2B | 87.8B |
| Shareholders' Equity | 40.1B | 34.3B | 26.7B | 25.9B | 25.3B | 38.2B | 46.0B | 37.6B | 46.3B | 52.6B | 44.9B |
| Cash & Short-term Investments | 6.52B | 6.09B | 7.97B | 9.68B | 8.06B | 8.10B | 12.7B | 6.84B | 13.2B | 14.6B | 9.55B |
| Cash Flow | |||||||||||
| Operating Cash Flow | 10.4B | 6.45B | 10.9B | 13.4B | 10.2B | 14.1B | 19.1B | 17.2B | 21.5B | 16.5B | 21.1B |
| Capital Expenditure | 1.61B | 1.89B | 2.62B | 3.37B | 4.43B | 4.45B | 4.39B | 4.02B | 3.37B | 4.11B | 3.90B |
| Free Cash Flow | - | 4.56B | 8.31B | 9.97B | 5.57B | 9.66B | 14.7B | 13.2B | 18.1B | 12.4B | 17.2B |
| Ratios | |||||||||||
| ROE | 9.8% | 7.0% | 23.3% | 38.0% | 27.9% | 34.2% | 31.6% | 1.0% | 37.0% | 34.7% | -1.5% |
| ROA | 4.1% | 2.7% | 7.5% | 11.7% | 7.7% | 12.3% | 13.3% | 0.3% | 14.6% | 13.3% | -0.5% |
| Net Profit Margin | 9.8% | 6.0% | 14.7% | 21.0% | 14.7% | 26.8% | 24.5% | 0.6% | 26.7% | 28.1% | -1.0% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Merck & Co. Inc dividends
- Dividend yield
- 2.29%
- Forward dividend
- 3.02 EUR
- Payout ratio
- 44.8%
- Ex-dividend date
- Sep 15, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | USD 8.18B | 3.30 | 44.8% |
| 2024 | USD 7.84B | 3.10 | 45.8% |
| 2023 | USD 7.34B | 2.90 | 2,011.8% |
| 2022 | USD 7.01B | 2.76 | 48.3% |
| 2021 | USD 6.61B | 2.62 | 50.7% |
| 2020 | USD 6.22B | 2.46 | 87.9% |
| 2019 | EUR 5.70B | 2.24 | 57.9% |
| 2018 | EUR 5.17B | 1.99 | 83.2% |
| 2017 | EUR 5.17B | 1.92 | 215.8% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 1048:1000 on Jun 3, 2021.
Who owns Merck & Co. Inc
- Insiders 0.06%
- Institutions 82.83%
- Public & others 17.11%
- Shares outstanding 2.47B
- Free float 2.46B
Merck & Co. Inc company profile
- Company name
- Merck & Co. Inc
- Ticker
- 6MK.F
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Employees
- 73,000
- Fiscal year end
- December
- Address
- 126 East Lincoln Avenue, Rahway, NJ, United States, 07065
- Phone
- 908 740 4000
- Website
- merck.com
About Merck & Co. Inc
Merck & Co., Inc. operates as a healthcare company worldwide. It offers human health pharmaceutical for various areas under the Keytruda, Keytruda Qlex, Welireg, Gardasil, ProQuad, M-M-R II, Varivax, Vaxneuvance, Capvaxive, RotaTeq, Pneumovax 23, Bridion, Prevymis, Dificid, Zerbaxa, Winrevair, Adempas/ Verquvo, Ohtuvayre, Lagevrio, Isentress/Isentress HD, Delstrigo, Pifeltro, Belsomra, Januvia, and Janumet brands. The company also provides veterinary pharmaceuticals, vaccines and health management solutions and services, such as livestock products under the Nuflor, Bovilis/Vista, Bovilis Cryptium, Banamine, Estrumate, Matrix, Resflor, Zuprevo, Revalor, Safe-Guard, M+Pac, Porcilis, Circumvent, Nobilis/Innovax, Paracox and Coccivac, Exzolt, Slice, Imvixa, Clynav, Aquavac/Norvax, Aquaflor, Flexolt brands; Allflex Livestock Intelligence solutions; and companion animal products under the Bravecto One-Month, Bravecto Injectable/Quantum, Bravecto TriUNO, Bravecto Plus, Sentinel Spectrum, Sentinel Flavor Tabs, Numelvi, Optimmune, Nobivac NXT, GilvetMab, Otomax, Mometamax, Mometamax Ultra, Posatex, Caninsulin/Vetsulin, Panacur, Safeguard, Regumate, Prestige, Scalibor/Exspot, Sure Petcare, and Home Again brands. It has development and commercialization agreement for three of Daiichi Sankyo's deruxtecan ADC candidates; AstraZeneca PLC to co-development and co-commercialize AstraZeneca's Lynparza products for multiple cancer types; licensed to develop, manufacture and commercialize LM-299, a novel investigational PD-1/VEGF bispecific antibody from LaNova; and collaboration agreement with Eisai Co., Ltd., Bayer AG, and Ridgeback Biotherapeutics LP, as well Moderna, Inc. Merck & Co., Inc. has strategic collaboration with Infinimmune, Inc. to discover and develop antibodies against multiple therapeutic targets. The company was founded in 1891 and is headquartered in Rahway, New Jersey.
Merck & Co. Inc management
10- Mr. Robert M. Davis J.D.Chairman, President & CEO · born 1967
- Ms. Caroline A. LitchfieldExecutive VP & CFO · born 1969
- Ms. Jennifer L. Zachary J.D.Executive VP & General Counsel · born 1978
- Dr. Dean Y. Li M.D., Ph.D.Executive VP & President of Merck Research Laboratories · born 1963
- Mr. Dalton E. Smart IIISenior VP of Finance, Principal Accounting Officer & Global Controller · born 1967
- Mr. Gaurav K. GuptaExecutive Vice President and Chief Information & Digital Officer
- Mr. Peter DannenbaumVice President of Investor Relations
- Mr. Chirfi GuindoExecutive Vice President of Strategic Access, Policy & Communications · born 1966
- Ms. Betty D. LarsonExecutive VP & Chief Human Resources Officer · born 1976
- Mr. Richard R. DeLuca Jr.Executive VP & President of Merck Animal Health · born 1963